Table 2 Patient characteristics
From: End-of-life care for idiopathic pulmonary fibrosis patients with acute exacerbation
| Â | All patients |
|---|---|
|  | (n = 539) |
Sex | Â |
Male | 429 (79.6) |
Female | 74 (13.7) |
missing | 36 (6.7) |
Age (median, SD) | 70 ± 8.3 |
Time from diagnosis to hospitalization | Â |
< 3months | 42 (7.8) |
More than 3 months but less than 6 months | 21 (3.9) |
More than 6 months but less than one year | 63 (11.7) |
> one year | 410 (76.1) |
Missing | 3 (0.5) |
Treatment before hospitalization | Â |
Antifibrotic agent | 249 (46.2) |
Corticosteroid | 180 (33.4) |
Immunosuppressive agent | 54 (10.0) |
Home oxygen therapy | 312 (57.9) |
Treatment provided newly after hospitalization | Â |
Corticosteroid | 329 (61.0) |
Immunosuppressive agent | 94 (17.4) |
Antifibrotic agent | 9 (1.7) |
Oxygen therapy after hospitalization | Â |
Conventional oxygen therapy | 179 (33.2) |
High Flow Nasal Cannula | 261 (48.4) |
Non-invasive positive pressure ventilation | 77 (14.3) |
Invasive mechanical ventilation | 13 (2.4) |
Missing | 9 (1.7) |